Teva signed an agreement to exclusively market and distribute the inhaler developed and manufactured by the Tel Aviv-based company Syqe Medical, the companies said in a statement Monday.
Syqe said it was the first time that a major global pharmaceutical company would market a medical cannabis product, according to The Times of Israel. The inhaler has been used at the Rambam Hospital in Haifa.
Israel’s Health Ministry was expected to approve the device for use by patients at home by 2017.
“Teva Israel is entering the field of medical cannabis out of a deep commitment to patients coping with pain, which is one of the company’s core therapeutic areas,” said its CEO, Avinoam Sapir, according to The Times of Israel.
Josefin Dolsten is a former news fellow at the Forward, writing about politics and culture, and editing the Sisterhood blog. She received an MA in Jewish Studies and Comparative Religion from the Hebrew University of Jerusalem and a BA in Government from Cornell University. Follow her on Twitter at @josefindolsten .